5-HT1-like receptors: A time to bid goodbye

Trends in Pharmacological Sciences

Volumn 19, Issue 8, 1998, Pages 311-316

  Saxena, P R ^c   De Vries, P ^a   Villalon C M ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYANOPINDOLOL; KETANSERIN; LISURIDE; MESULERGINE; METHYSERGIDE; METITEPINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 18 RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG;

CAPILLARY FLOW; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERTENSION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SEROTONINERGIC SYSTEM; ANIMAL; ARTICLE; CLASSIFICATION; HISTORY; NOMENCLATURE;

ANIMALS; HISTORY, 20TH CENTURY; HUMANS; RECEPTORS, SEROTONIN; TERMINOLOGY;

EID: 0032134722     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(98)01228-0     Document Type: Article

References (79)

1. Bradley P. B. et al. Neuropharmacology. 25:1986;563-576.
2. Hoyer D. et al. Pharmacol. Rev. 46:1994;157-203.
3. Saxena P. R., Ferrari M. D. Trends Pharmacol. Sci. 10:1989;200-204.
4. Feniuk W., Humphrey P. P. A. Saxena P. R., Wallis D. I., Wouters W., Bevan P. Cardiovascular Pharmacology of 5-Hydroxytryptamine. 1990;68-80 Kluwer Academic Publishers.
5. Saxena P. R., Villalón C. M. J. Cardiovasc. Pharmacol. 15 (Suppl. 7):1990;S17-S34.
6. Leff P., Martin G. R., Morse J. M. Br. J. Pharmacol. 91:1987;321-331.
7. Martin G. R., Leff P., Cambridge D., Barrett V. J. Naunyn-Schmiedeberg's Arch. Pharmacol. 336:1987;365-373.
8. Humphrey P. P. A. et al. Br. J. Pharmacol. 94:1988;1123-1132.
9. Humphrey P. P. A., Apperley E., Feniuk W., Perren M. J. Saxena P. R., Wallis D. I., Wouters W., Bevan P. Cardiovascular Pharmacology of 5-Hydroxytryptamine. 1990;417-431 Kluwer Academic Publishers.
10. Sumner M. J., Humphrey P. P. A. Br. J. Pharmacol. 99:1990;219-220.
11. Sumner M. J., Feniuk W., Humphrey P. P. A. Br. J. Pharmacol. 97:1989;292-300.
12. Martin G. R. Pharmacol. Ther. 62:1994;283-324.
13. Waeber C., Schoeffter P., Palacios J. M., Hoyer D. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;595-601.
14. Deckert V., Pruneau D., Elghozi J. L. Br. J. Pharmacol. 112:1994;939-945.
15. Den Boer M. O., Villalón C. M., Saxena P. R. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;509-515.
16. Villalón C. M. et al. Br. J. Pharmacol. 116:1995;2778-2784.
17. Schoeffter P., Waeber C., Palacios J. M., Hoyer D. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;602-608.
18. Walsh D. M., Beattie D. T., Connor H. E. Eur. J. Pharmacol. 287:1995;79-84.
19. Clitherow J. W. et al. J. Med. Chem. 37:1994;2253-2257.
20. Skingle M. et al. Behav. Brain Res. 73:1996;157-161.
21. Pauwels P. J. CNS Drug Rev. 2:1996;415-428.
22. De Vries P., Heiligers J. P. C., Villalón C. M., Saxena P. R. Br. J. Pharmacol. 118:1996;85-92.
23. Villalón C. M., Sánchez-López A., Centurión D. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;550-556.
24. Göthert M. et al. Behav. Brain Res. 73:1996;89-92.
25. Bühlen M., Fink K., Boing C., Göthert M. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;281-289.
26. Schoeffter P., Ullmer C., Gutierrez M., Weitz-Schmidt G., Lübbert H. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;580-582.
27. Kaumann A. J., Frenken M., Posival H., Brown A. M. Circulation. 90:1994;1141-1153.
28. Terrón J. A. Eur. J. Pharmacol. 300:1996;109-112.
29. Sgard F., Faure C., Graham D. Cardiovasc. Res. 31:1996;793-799.
30. Hamel E. et al. Mol. Pharmacol. 44:1993;242-246.
31. Craig D. A., Martin G. R. Br. J. Pharmacol. 109:1993;609-611.
32. Molderings G. J., Frolich D., Likungu J., Göthert M. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;272-280.
33. Terrón J. A. Br. J. Pharmacol. 118:1996;1421-1428.
34. De Vries P., Villalón C. M., Heiligers J. P. C., Saxena P. R. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;90-99.
35. Villalón C. M., Centurión D., Luján-Estrada M., Terrón J. A., Sánchez-López A. Br. J. Pharmacol. 120:1997;1319-1327.
36. Villalón C. M., Heiligers J. P. C., Centurión D., De Vries P., Saxena P. R. Br. J. Pharmacol. 121:1997;1187-1195.
37. Carter D., Champney M., Hwang B., Eglen R. M. Eur. J. Pharmacol. 280:1995;243-250.
38. Leung E., Walsh L. K. M., Pulido-Rios M. T., Eglen R. M. Br. J. Pharmacol. 117:1996;926-930.
39. Schoeffter P., Ullmer C., Bobirnac I., Gabbiani G., Lübbert H. Br. J. Pharmacol. 117:1996;993-994.
40. Price G. W. et al. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;312-320.
41. De Vries P., Apaydin S., Villalón C. M., Heiligers J. P. C., Saxena P. R. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;423-430.
42. Weinshank R. L., Zgombick J. M., Macchi M. J., Branchek T. A., Hartig P. R. Proc. Natl. Acad. Sci. U. S. A. 89:1992;3630-3634.
43. Hartig P. R., Hoyer D., Humphrey P. P. A., Martin G. R. Trends Pharmacol. Sci. 17:1996;103-105.
44. Bouchelet I., Cohen Z., Case B., Seguela P., Hamel E. Mol, Pharmacol, 50:1996;219-223.
45. Branchek A. et al. Olesen J., Moskowitz M. A. Experimental Headache Models. 1995;125-134 Lippincott-Raven Publishers.
46. Ullmer C., Schmuck K., Kalkman H. O., Lübbert H. FEBS Lett. 370:1995;215-221.
47. Eglen R. M., Jasper J. R., Chang D. A., Martin G. R. Trends Pharmacol. Sci. 18:1997;104-107.
48. Saxena P. R. Pharmacol. Ther. 66:1995;339-368.
49. Villalón C. M., De Vries P., Saxena P. R. Drug Discovery Today. 2:1997;294-300.
50. Ludwig C., Schmidt A. Arb. a. d. Physiol. Anstalt z. Leipzig. 3:1868;1.
51. Rapport M. M., Green A. A., Page I. H. J. Biol. Chem. 176:1948;1243-1251.
52. Rapport M. M. J. Biol. Chem. 180:1949;961-969.
53. Hamlin K. E., Fischer F. E. J. Am. Chem. Soc. 73:1951;5007-5008.
54. Speeter M. E., Heinzelmann R. V., Weisblat D. I. J. Am. Chem. Soc. 73:1951;5514-5515.
55. Erspamer V. Pharmacol. Rev. 6:1954;425-487.
56. Erspamer V., Asero B. Nature. 169:1952;800-801.
57. Page I. H. Physiol. Rev. 34:1954;563-588.
58. Gaddum J. H., Picarelli Z. P. Br. J. Pharmacol. 12:1957;323-328.
59. Saxena P. R., Houwelingen P. V., Bonta I. L. Eur. J. Pharmacol. 13:1971;295-305.
60. Saxena P. R. Headache. 12:1972;44-54.
61. Saxena P. R. Eur. J. Pharmacol. 27:1974;99-105.
62. Bennett J. L., Aghajanian G. K. Life Sci. 15:1974;1935-1944.
63. Peroutka S. J., Snyder S. H. Mol. Pharmacol. 16:1979;687-699.
64. Pedigo N. W., Yamamura H. I., Nelson D. L. J. Neurochem. 36:1981;220-226.
65. Gozlan H., El Mestikawy S., Pichat L., Glowinski J., Hamon M. Nature. 305:1983;140-142.
66. Middlemiss D. N., Fozard J. R. Eur. J. Pharmacol. 90:1983;151-153.
67. Feniuk W., Humphrey P. P. A., Watts A. D. Br. J. Pharmacol. 73:1981;191P.
68. Engel G. et al. Naunyn-Schmiedeberg's Arch. Pharmacol. 324:1983;116-124.
69. Feniuk W., Humphrey P. P. A., Watts A. D. Br. J. Pharmacol. 82:1984;209P.
70. Feniuk W., Humphrey P. P., Perren M. J., Watts A. D. Br. J. Pharmacol. 86:1985;697-704.
71. Saxena P. R., Lawang A. Arch. Int. Pharmacodyn. Ther. 277:1985;235-252.
72. Martin G. R., Leff P., Cambridge D., Barrett V. J. Naunyn-Schmiedeberg's Arch. Pharmacol. 336:1987;365-373.
73. Saxena P. R., Verdouw P. D. Br. J. Pharmacol. 84:1985;533-544.
74. Saxena P. R., Mylecharane E. J., Heiligers J. Naunyn-Schmiedeberg's Arch. Pharmacol. 330:1985;121-129.
75. Humphrey P. P. A. Bevan J. A., Fujiwara M., Maxwell R. A., Mohri K., Shibata S., Toda N. Proceedings of IVth Vascular Neuroeffector Mechanisms Symposium. 1983;237-242 Raven Press.
76. Verdouw P. D., Jennewein H. M., Heiligers J., Duncker D. J., Saxena P. R. Eur. J. Pharmacol. 102:1984;499-509.
77. Fozard J. R. Naunyn-Schmiedeberg's Arch. Pharmacol. 326:1984;36-44.
78. Richardson B. P., Engel G., Donatsch P., Stadler P. A. Nature. 316:1985;126-131.
79. Bradley P. B. et al. Neuropharmacology. 25:1986;563-576.